Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022;158:495–503.

• PubMed
Arnold M, Singh D, Laversanne M, Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022;158:495–503.)| false
• Search Google Scholar
• Export Citation

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49.

• PubMed
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49.)| false
• Search Google Scholar
• Export Citation

Ernst M, Giubellino A. The current state of treatment and future directions in cutaneous malignant melanoma. Biomedicines 2022;10:822.

• PubMed
Ernst M, Giubellino A. The current state of treatment and future directions in cutaneous malignant melanoma. Biomedicines 2022;10:822.)| false
• Search Google Scholar
• Export Citation

Kakish H, Pawar O, Bhatty M, et al. Disparities in the receipt of systemic treatment in metastatic melanoma. Am J Clin Oncol 2024;47:239–245.

• PubMed
Kakish H, Pawar O, Bhatty M, Disparities in the receipt of systemic treatment in metastatic melanoma. Am J Clin Oncol 2024;47:239–245.)| false
• Search Google Scholar
• Export Citation

Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm 2014;20:346–356.

• PubMed
Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm 2014;20:346–356.)| false
• Search Google Scholar
• Export Citation

Qian Y, Johannet P, Sawyers A, et al. The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (1975–2016). J Am Acad Dermatol 2021;84:1585–1593.

• PubMed
Qian Y, Johannet P, Sawyers A, The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (1975–2016). J Am Acad Dermatol 2021;84:1585–1593.)| false
• Search Google Scholar
• Export Citation

Lam M, Zhu JW, Hu A, et al. Racial differences in the prognosis and survival of cutaneous melanoma from 1990 to 2020 in North America: a systematic review and meta-analysis. J Cutan Med Surg 2022;26:181–188.

• PubMed
Lam M, Zhu JW, Hu A, Racial differences in the prognosis and survival of cutaneous melanoma from 1990 to 2020 in North America: a systematic review and meta-analysis. J Cutan Med Surg 2022;26:181–188.)| false
• Search Google Scholar
• Export Citation

Singh SRK, Malapati SJ, Kumar R, et al. NCDB analysis of melanoma 2004–2015: epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and real-world survival benefit of immunotherapy approval. Cancers (Basel) 2021;13:1455.

• PubMed
Singh SRK, Malapati SJ, Kumar R, NCDB analysis of melanoma 2004–2015: epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and real-world survival benefit of immunotherapy approval. Cancers (Basel) 2021;13:1455.)| false
• Search Google Scholar
• Export Citation

Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386–389.

• PubMed
Rigel DS, Rivers JK, Kopf AW, Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386–389.)| false
• Search Google Scholar
• Export Citation

Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014;70:847–857.e18.

• PubMed
Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014;70:847–857.e18.)| false
• Search Google Scholar
• Export Citation

Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep 2013;2:24–34.

• PubMed
Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep 2013;2:24–34.)| false
• Search Google Scholar
• Export Citation

Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241–250.

• PubMed
Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241–250.)| false
• Search Google Scholar
• Export Citation

Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400–407.

• PubMed
Tan MH, Mester JL, Ngeow J, Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400–407.)| false
• Search Google Scholar
• Export Citation

Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 2017;36:77–90.

• PubMed
Leachman SA, Lucero OM, Sampson JE, Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 2017;36:77–90.)| false
• Search Google Scholar
• Export Citation

Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41:45–60.

• PubMed
Gandini S, Sera F, Cattaruzza MS, Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41:45–60.)| false
• Search Google Scholar
• Export Citation

Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006;24:3172–3177.

• PubMed
Whiteman DC, Stickley M, Watt P, Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006;24:3172–3177.)| false
• Search Google Scholar
• Export Citation

Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492.

• PubMed
Gershenwald JE, Scolyer RA, Hess KR, Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492.)| false
• Search Google Scholar
• Export Citation

Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459–465.

• PubMed
Margolin K, Ernstoff MS, Hamid O, Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459–465.)| false
• Search Google Scholar
• Export Citation

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.

• PubMed
Hodi FS, O’Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.)| false
• Search Google Scholar
• Export Citation

Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017;18:611–622.

• PubMed
Ascierto PA, Del Vecchio M, Robert C, Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017;18:611–622.)| false
• Search Google Scholar
• Export Citation

Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–384.

• PubMed
Weber JS, D’Angelo SP, Minor D, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–384.)| false
• Search Google Scholar
• Export Citation

Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25:941–946.

• PubMed
Ascierto PA, Ferrucci PF, Fisher R, Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25:941–946.)| false
• Search Google Scholar
• Export Citation

Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol 2019;5:187–194.

• PubMed
Ascierto PA, Long GV, Robert C, Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol 2019;5:187–194.)| false
• Search Google Scholar
• Export Citation

Kluger HM, Chiang V, Mahajan A, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 2019;37:52–60.

• PubMed
Kluger HM, Chiang V, Mahajan A, Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 2019;37:52–60.)| false
• Search Google Scholar
• Export Citation

Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24–34.

• PubMed
Tawbi HA, Schadendorf D, Lipson EJ, Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24–34.)| false
• Search Google Scholar
• Export Citation

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022;40:127–137.

• PubMed
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022;40:127–137.)| false
• Search Google Scholar
• Export Citation

Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019;20:e378–389.

• PubMed
Amaria RN, Menzies AM, Burton EM, Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019;20:e378–389.)| false
• Search Google Scholar
• Export Citation

Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26:475–484.

• PubMed
Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26:475–484.)| false
• Search Google Scholar
• Export Citation

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813–823.

• PubMed
Patel SP, Othus M, Chen Y, Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813–823.)| false
• Search Google Scholar
• Export Citation

van Akkooi AC, Hieken TJ, Burton EM, et al. Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 2022;29:3694–3708.

• PubMed
van Akkooi AC, Hieken TJ, Burton EM, Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 2022;29:3694–3708.)| false
• Search Google Scholar
• Export Citation

Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019;25:454–461.

• PubMed
Huang AC, Orlowski RJ, Xu X, A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019;25:454–461.)| false
• Search Google Scholar
• Export Citation

Sharon CE, Tortorello GN, Ma KL, et al. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Ann Oncol 2023;34:806–812.

• PubMed
Sharon CE, Tortorello GN, Ma KL, Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Ann Oncol 2023;34:806–812.)| false
• Search Google Scholar
• Export Citation

Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24:1655–1661.

• PubMed
Blank CU, Rozeman EA, Fanchi LF, Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24:1655–1661.)| false
• Search Google Scholar
• Export Citation

Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023;34:420–430.

• PubMed
Versluis JM, Menzies AM, Sikorska K, Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023;34:420–430.)| false
• Search Google Scholar
• Export Citation

Rozeman EA, Menzies AM, van Akkooi AC, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20:948–960.

• PubMed
Rozeman EA, Menzies AM, van Akkooi AC, Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20:948–960.)| false
• Search Google Scholar
• Export Citation

Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 2021;27:256–263.

• PubMed
Rozeman EA, Hoefsmit EP, Reijers ILM, Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 2021;27:256–263.)| false
• Search Google Scholar
• Export Citation

Blank CU, Reijers ILM, Pennington T, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol 2020;38(Suppl):Abstract 10002.

• PubMed
Blank CU, Reijers ILM, Pennington T, First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol 2020;38(Suppl):Abstract 10002.)| false
• Search Google Scholar
• Export Citation

Reijers ILM, Rozeman EA, Menzies AM, et al. Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial. Ann Oncol 2019;30:Abstract V541.

• PubMed
Reijers ILM, Rozeman EA, Menzies AM, Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial. Ann Oncol 2019;30:Abstract V541.)| false
• Search Google Scholar
• Export Citation

Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649–1654.

• PubMed
Amaria RN, Reddy SM, Tawbi HA, Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649–1654.)| false
• Search Google Scholar
• Export Citation

Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 2022;611:155–160.

• PubMed
Amaria RN, Postow M, Burton EM, Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 2022;611:155–160.)| false
• Search Google Scholar
• Export Citation

Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018;19:181–193.

• PubMed
Amaria RN, Prieto PA, Tetzlaff MT, Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018;19:181–193.)| false
• Search Google Scholar
• Export Citation

Long GV, Saw RP, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol 2019;20:961–971.

• PubMed
Long GV, Saw RP, Lo S, Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF^V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol 2019;20:961–971.)| false
• Search Google Scholar
• Export Citation

Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med 2021;27:1789–1796.

• PubMed
Dummer R, Gyorki DE, Hyngstrom J, Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med 2021;27:1789–1796.)| false
• Search Google Scholar
• Export Citation